Page 1,560«..1020..1,5591,5601,5611,562..1,5701,580..»

How to Trade these Stock After an unavoidable Selloff: Puma Biotechnology, Inc. (PBYI), BofI Holding, Inc. (BOFI) – StockNewsJournal

Posted: May 23, 2017 at 11:43 am

How to Trade these Stock After an unavoidable Selloff: Puma Biotechnology, Inc. (PBYI), BofI Holding, Inc. (BOFI)
StockNewsJournal
Puma Biotechnology, Inc. (NASDAQ:PBYI) market capitalization at present is $1.42B at the rate of $37.80 a share. The firm's price-to-sales ratio was noted 0.00 in contrast with an overall industry average of 100.20. Most of the active traders and ...

and more »

Read the rest here:
How to Trade these Stock After an unavoidable Selloff: Puma Biotechnology, Inc. (PBYI), BofI Holding, Inc. (BOFI) - StockNewsJournal

Posted in Biotechnology | Comments Off on How to Trade these Stock After an unavoidable Selloff: Puma Biotechnology, Inc. (PBYI), BofI Holding, Inc. (BOFI) – StockNewsJournal

Puma Biotechnology, Inc. (PBYI) Has Finally Shown Its Full Hand Via The Chart Setup – NY Stock News

Posted: May 23, 2017 at 11:43 am

Puma Biotechnology, Inc. (PBYI) Has Finally Shown Its Full Hand Via The Chart Setup
NY Stock News
Puma Biotechnology, Inc. (PBYI) has been having a set of eventful trading activity and it is clear from an examination of the charts that traders are now fully aware of the company's key metrics. A deeper exploration of the setup is sure to yield a ...

and more »

Read the rest here:
Puma Biotechnology, Inc. (PBYI) Has Finally Shown Its Full Hand Via The Chart Setup - NY Stock News

Posted in Biotechnology | Comments Off on Puma Biotechnology, Inc. (PBYI) Has Finally Shown Its Full Hand Via The Chart Setup – NY Stock News

Puma Biotechnology: Shares on the prowl – Times of India

Posted: May 23, 2017 at 11:43 am

BUZZ-Puma Biotechnology: Shares on the prowl:BUZZ-Puma Biotechnology: Shares on the prowl

** Puma Biotechnology shares soar 50.3 pct to $56.80 in heavy Monday morning trading; shares rise as high as $69.35, halted multiple times for volatility

** U.S. Food and Drug Administration posts documents reviewing Puma's neratinib for treating breast cancer ahead of FDA advisory committee meeting on the product on Weds

** Based on sensitivity analyses conducted, results appear to be generally similar to the primary analysis results, supporting an effect of neratinib, FDA staffers say in review documents

** Options market has been pricing in a move about 63 pct, positive or negative, in PBYI shares in reaction to neratinib review, JPMorgan analyst Cory Kasimov said in research note last week

** Short interest in PBYI shares stood at 21.5 pct of shares outstanding as of Apr 27, according to Thomson Reuters data

** Five analysts rate PBYI shares a "buy" or "strong buy", two rate "hold", according to TR data; median price target is $80

** PBYI shares have nearly doubled in 2017, against 9.7 pct rise for Nasdaq Biotechnology index

(This story has not been edited by timesofindia.com and is autogenerated from a syndicated feed we subscribe to.)

RELATED

Shudder

AD BY AVANIR 2016 Avanir Pharmaceuticals, Inc, All Rights Reserved. Avanir is a trademark or Avanir Pharmaceuticals, Inc.

Eos

Read more:
Puma Biotechnology: Shares on the prowl - Times of India

Posted in Biotechnology | Comments Off on Puma Biotechnology: Shares on the prowl – Times of India

Stem cell treatments ready to replace medicine in 10 years: Expert – Jakarta Post

Posted: May 23, 2017 at 11:42 am

Currently, there are only 11 hospitals that are authorized to give stem cell treatments in Indonesia. (Shutterstock/File)

Developments in science and technology have enabled humankind to achieve the unthinkable, including advancements in healthcare. In the next 10 years, patients may not even need medicine to cure certain illnesses as reported by kompas.com.

Principal investigator of Stem Cell and Cancer Institute, Dr. Yuyus Kusnadi, said health scientists are developing stem cell treatments. Stem cells are cells with the ability to renew or regenerate any kind of cells.

Degenerative conditions such as kidney failure and the weakening of heart muscles in the future may be cured by injecting stem cells into the patients body.

Stem cells can be obtained from umbilical cord blood that is kept in a stem cell bank, back bone marrow and fat. However, fat and bone marrow will decline in quality as a person grows older. Stem cells stored in a stem cell bank can be used for future treatments if needed.

Read also: Scientists take first steps to growing human organs in pigs

Health treatments using stem cells exist today although they are not yet developed due to limitations in funding and technology. Yuyus said in Indonesia, those who are allowed stem cell treatment are those who have no option.

For now, stem cell treatment require a doctors approval. Its still subjective, he said.

For those with recommendations for stem cell treatment, the stem cell is obtained from blood or fat. Manipulation in the laboratory is needed to strengthen the stem cell.

Although stem cell treatments are not yet popular these days, Yuyus is optimistic, Lets wait five to ten more years. The current use of medicine only stops symptoms and does not fix the sickness, he said.

Stem cell treatments will not be cheap either, as it will cost patients up to hundreds of millions of rupiah.

Currently, there are only 11 hospitals that are authorized to give stem cell treatments in Indonesia. The hospitals right to provide stem cell treatments is regulated in the Health Ministers Regulation no. 32, 2014 on the Incorporation of Medical Research Service and Education of Tissue and Stem Cell Centers.

Hospitals authorized to provide stem cell treatments in Indonesia include Rumah Sakit Cipto Mangun Kusumo, RS. Sutomo, RS M. Djamil, RS. Persahabatan, RS. Fatmawati, RS. Dharmais, RS. Harapan Kita, RS. Hasan Sadikin, RS. Kariadi, RS. Sardjito and RS. Sanglah. (asw)

Read the original post:
Stem cell treatments ready to replace medicine in 10 years: Expert - Jakarta Post

Posted in Cell Medicine | Comments Off on Stem cell treatments ready to replace medicine in 10 years: Expert – Jakarta Post

Study identifies RNA molecule that shields breast cancer stem cells … – Medical Xpress

Posted: May 23, 2017 at 11:42 am

May 22, 2017 Researchers from Princeton University's Department of Molecular Biology have identified a small RNA molecule that helps maintain the activity of stem cells in both healthy and cancerous breast tissue. Above, the microscopic image shows different cell types in the normal mammary ducts of a mouse. The luminal cells (red) are milk-producing cells and the basal cells (green) have contractile functions, but also are responsible for regenerating the mammary gland, as they contain the majority of mammary gland stem cells. These stem cells, located in the outer layer of the gland, are exposed to microenvironmental factors and interact with various immune cells, including macrophages, in the mammary gland. Credit: Toni Celi-Terrassa and Yibin Kang, Department of Molecular Biology

Researchers from Princeton University's Department of Molecular Biology have identified a small RNA molecule that helps maintain the activity of stem cells in both healthy and cancerous breast tissue. The study, which will be published in the June issue of Nature Cell Biology, suggests that this "microRNA" promotes particularly deadly forms of breast cancer and that inhibiting the effects of this molecule could improve the efficacy of existing breast cancer therapies.

Stem cells give rise to the different cell types in adult tissues but, in order to maintain these tissues throughout adulthood, stem cells must retain their activity for decades. They do this by "self-renewing," dividing to form additional stem cells, and resisting the effects of environmental signals that would otherwise cause them to prematurely differentiate into other cell types.

Many tumors also contain so-called "cancer stem cells" that can drive tumor formation. Some tumors, such as triple-negative breast cancers, are particularly deadly because they contain large numbers of cancer stem cells that self-renew and resist differentiation.

To identify factors that help non-cancerous mammary gland stem cells (MaSCs) resist differentiation and retain their capacity to self-renew, Yibin Kang, the Warner-Lambert/Parke-Davis Professor of Molecular Biology, and colleagues searched for short RNA molecules called microRNAs that can bind and inhibit protein-coding messenger RNAs to reduce the levels of specific proteins. The researchers identified one microRNA, called miR-199a, that helps MaSCs retain their stem-cell activity by suppressing the production of a protein called LCOR, which binds DNA to regulate gene expression. The team showed that when they boosted miR-199a levels in mouse MaSCs, they suppressed LCOR and increased normal stem cell function. Conversely, when they increased LCOR levels, they could curtail mammary gland stem cell activity.

Kang and colleagues found that miR-199a was also expressed in human and mouse breast cancer stem cells. Just as boosting miR-199a levels helped normal mammary gland stem cells retain their activity, the researchers showed that miR-199a enhanced the ability of cancer stem cells to form tumors. By increasing LCOR levels, in contrast, they could reduce the tumor-forming capacity of the cancer stem cells. In collaboration with researchers led by Zhi-Ming Shao, a professor at Fudan University Shanghai Cancer Center in China, Kang's team found that breast cancer patients whose tumors expressed large amounts of miR-199a showed poor survival rates, whereas tumors with high levels of LCOR had a better prognosis.

Kang and colleagues found that LCOR sensitizes cells to the effects of interferon-signaling molecules released from epithelial and immune cells, particularly macrophages, in the mammary gland. During normal mammary gland development, these cells secrete interferon-alpha to promote cell differentiation and inhibit cell division, the researchers discovered. By suppressing LCOR, miR-199a protects MaSCs from interferon signaling, allowing MaSCs to remain undifferentiated and capable of self-renewal.

The microRNA plays a similar role during tumorigenesis, protecting breast cancer stem cells from the effects of interferons secreted by immune cells present in the tumor. "This is a very nice study linking a normal and malignant mammary gland stem cell program to protection from immune modulators," said Michael Clarke, the Karel H. and Avice N. Beekhuis Professor in Cancer Biology at Stanford School of Medicine, Institute of Stem Cell Biology and Regenerative Medicine, who first discovered breast cancer stem cells but was not involved in this study. "It clearly has therapeutic implications for designing strategies to rationally target the breast cancer stem cells with immune modulators."

Toni Celi -Terrassa, an associate research scholar in the Kang lab and the first author of the study, said, "This study unveils a new property of breast cancer stem cells that give them advantages in their interactions with the immune system, and therefore it represents an excellent opportunity to exploit for improving immunotherapy of cancer."

"Interferons have been widely used for the treatment of multiple cancer types," Kang said. "These treatments might become more effective if the interferon-resistant cancer stem cells can be rendered sensitive by targeting the miR-199a-LCOR pathway."

Explore further: Scientists identify chain reaction that shields breast cancer stem cells from chemotherapy

More information: Toni Celi-Terrassa et al, Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199aLCOR axis, Nature Cell Biology (2017). DOI: 10.1038/ncb3533

Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.

Many cancer patients that receive chemotherapy go into remission at first, but relapse after treatment is discontinued. There is increasing evidence that this is due to the presence of cancer stem cellscells that reproduce ...

In the breast, cancer stem cells and normal stem cells can arise from different cell types but tap into distinct yet related stem cell programs, according to Whitehead Institute researchers. The differences between these ...

Stem cells are different from all other cells in our body because they retain the remarkable genetic plasticity to self-renew indefinitely as well as develop into cell types with more specialized functions. However, this ...

During breast-tissue development, a transcription factor called SLUG plays a role in regulating stem cell function and determines whether breast cells will mature into luminal or basal cells.

A key step in developing effective cancer therapies is identifying differences between normal, healthy cells and cancer cells these differences can then be exploited to specifically kill tumour cells.

The average human pair of lungs is permeated by a network of about 164 feet of blood vessels (roughly the width of a football field), including microscopic blood capillaries, which facilitate the diffusion of oxygen into ...

Researchers from Princeton University's Department of Molecular Biology have identified a small RNA molecule that helps maintain the activity of stem cells in both healthy and cancerous breast tissue. The study, which will ...

A multi-institutional team based at Massachusetts General Hospital (MGH) has discovered how a potential treatment strategy for Huntington disease (HD) produces its effects, verified its action in human cells and identified ...

Some major cell-to-cell communication networks were first studied in worms. Now those worms, Caenorhabditis elegans, are being used to understand the influence of cancer mutations on those networks, report researchers at ...

Anti-aging serums, wrinkle creams and surgeries provide the promise of a youthful appearance that can go only skin-deep.

In a turnabout, a biochemical self-destruct trigger found in many other types of cells appears to guard the lives of brain cells during an infection with West Nile virus.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more here:
Study identifies RNA molecule that shields breast cancer stem cells ... - Medical Xpress

Posted in Cell Medicine | Comments Off on Study identifies RNA molecule that shields breast cancer stem cells … – Medical Xpress

Stem Cell Therapy is One Step Closer to Becoming Law in Texas – PR Newswire (press release)

Posted: May 23, 2017 at 11:41 am

"At StemGenex, we are committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells," said Alexander. "Specifically, we use adipose-derived adult stem cell therapy for patients battling conditions such as Multiple Sclerosis, Parkinson's disease, COPD, Rheumatoid Arthritis and Osteoarthritis. We are also committed to the science of stem cell therapy and sponsor five clinical outcome studiesregistered with theNational Institute of Health (NIH) for these diseases."

"What I personally witnessed before the start of StemGenex were patients who had exhausted conventional medical treatments but wanted to try alternative therapies. I was one of them, suffering from severe Rheumatoid Arthritis. Ihad only three options; I could seek a clinical trial, travel to outside of the U.S. to try alternative therapies such as stem cell treatment or petition the FDA for access to drugs under the agency's "expanded access," or "compassionate use" program. Now, new state laws, built on model legislation from the Goldwater Institute in Arizona, will potentially allow doctors and patients to make their own informed decisions on treatments that have cleared the safety phase of FDA testing."

Last year, in a move that was seen by some as a response to "Right to Try" laws, the 21st Century Cures Act, a landmark piece of legislation focused on medical innovation and medical research, was signed into law by President Obama. This Act provides the FDA with the flexibility to accelerate how it evaluates regenerative medicine treatments, such as stem cell therapies, while maintaining its high standards of safety and efficacy.

"We're on the cusp of a major change on how patients can access stem cell therapy," saidAlexander. "Today, new treatments and advances in research are giving new hope to people affected by a wide range of autoimmune and degenerative illnesses," said Alexander. "StemGenex Medical Group is proud to offer the highest quality of care and to potentially help those with unmet clinical needs improve their quality of life."

ABOUT StemGenex Medical Group StemGenex Medical Group is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides stem cell therapy options for individuals suffering with inflammatory and degenerative illnesses. Committed to the science and innovation of stem cell treatment,StemGenex sponsors five clinical outcome studiesregistered with theNational Institutes of Health ("NIH") for Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease ("COPD") and Osteoarthritis. These have been established to formally document and evaluate the quality of life changes in individuals following adipose-derived stem cell treatment.

Contact: Jamie Schubert, Director of Media & Community Relations jschubert@StemGenex.com, (858) 242-4243

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stem-cell-therapy-is-one-step-closer-to-becoming-law-in-texas-300461859.html

SOURCE StemGenex

http://www.stemgenex.com

Follow this link:
Stem Cell Therapy is One Step Closer to Becoming Law in Texas - PR Newswire (press release)

Posted in Cell Therapy | Comments Off on Stem Cell Therapy is One Step Closer to Becoming Law in Texas – PR Newswire (press release)

Stem-cell therapy for cancer comes closer home – The New Indian Express

Posted: May 23, 2017 at 11:41 am

BENGALURU:Full-fledged treatment for cancer and bone-related ailments using stem-cell within the state could soon be a possibility if a plan of a world renowned surgeon from the state succeeds.

Dr A A Shetty is a highly decorated orthopedic surgeon and professor based in the UK who won the Nobel equivalent of surgery called the Hunterian Medal, this year. In his aim to bring about next level cancer and orthopedic treatment, he has already set up two big stem cell research labs - one in Dharwad and another in Mangaluru, a few years back at a cost of around 20 to 25 crore. A hospital that will treat stem-related ailments has also been envisaged at a total cost of around Rs 200 to 250 crore.

Setting up the labs is part of a three-step goal. After setting up the labs, the next step will be producing the stem cells, whether it be for bone ailments, treatment for cervical cancer etc. Then the third step will be the application of these stem cells through our hospital or through tie-ups with other hospitals. I have already received the funding for setting up the hospital, says Dr Shetty in an interaction with CE in Bengaluru. He is originally from a small village called Asode in Udupi district.

The lab in Dharwad is located at SDM College and is being backed by Shri Dharmasthala Manjunatheshwara and will be primarily working on blood cancer and thalassemia treatment. The one in Mangaluru is located at K.S. Hegde Medical Academy (KSHEMA) and is backed by the NITTE group. It will work on cartilage and bone fracture treatments.The effort is no doubt for profit. We will charge the rich but the poor will be treated for free at our hospital, he says.

Already, Shetty has recruited a number of top stem cell researchers from the state who are presently abroad. I have recruited researchers who were doing their postdoc studies in Japan, South Korea. Presently there are four of them working at the two labs, he says. Shetty ultimately wants to settle in Karnataka and hopes to achieve his goal by 2020. The third stage of his plan also requires expertise in various cutting edge technologies such as robotics, computing and he will also be recruiting people who specialize in these fields.

Cancer Vaccination

Shetty also hopes to make cancer vaccination a possibility. Giving an example of cervical cancer, Shetty says, Few cancers can be vaccinated. Cervical cancer, one of the most rampant cancers, is one of them. We will use stems derived from iPS cell. In the UK, the vaccine cost 60 pounds. Our aim is to develop it and sell it at a very low cost, as low as Rs 100, he adds. Induced Pluripotent Stem Cells or iPS Cells are derived from the blood and skiwwn cells and can be reprogrammed to provide an unlimited source of any type of human cell.

Stem cells for Arthritis In 2013, Shetty devised a minimally invasive procedure to treat arthritis using stem cells. When the cartilage between the bones begin to erode, the bones rub against each other and cause severe pain. Shetty treated a patient suffering from knee arthritis. He drilled a hole into the patients knee bone and released stem cells that could grow into the cartilage. In all, the procedure lasted just 30 minutes. Shetty has already done as many as two dozen such procedures in India.

Trauma Center Shetty also says that he wants to develop and provide integrated trauma services. If a patient survives the golden hour then he/she can be saved. Majority die in the first hour of trauma. My integrated services will have specialized suits that will help reduce blood loss and will have other know-how. I am negotiating with the International Rotary on this, he adds. This may be established either in Mangalore or Bangalore.

Dr Vishal Rao, head and neck oncology surgeon at HCG Hospitals says that stem cells research is in the mid-stage of development and has great potential to grow in India. The IT and BT ministry is already taking great steps by encouraging startups on these lines, starting various schemes, he says. Vishal also pointed out that a number of private organizations, hospitals and individuals like those like Dr Shetty are also investing in the field.

The rest is here:
Stem-cell therapy for cancer comes closer home - The New Indian Express

Posted in Cell Therapy | Comments Off on Stem-cell therapy for cancer comes closer home – The New Indian Express

How a revolutionary stem cell treatment could save your heart – Express.co.uk

Posted: May 23, 2017 at 11:41 am

NC

Yet today the 59-year-old father of two is planning a dream family trip to South Africa, something that would have been unthinkable a mere nine months ago.

The reason for this remarkable transformation is that last September Gordon, who suffered from severe heart failure after a series of heart attacks, underwent revolutionary stem cell therapy to repair the diseased muscle tissue in his heart.

I couldnt walk up the stairs without having stabbing pains in my heart and burning in my lungs. Sometimes I had to crawl for the last few steps.

I felt so low and helpless, says Gordon, who is married to Joanne, 50, and lives in Thorneholme, East Yorkshire.

Within a week of the operation I could climb the stairs again. Small things like that have made a huge difference to my life.

More than a million people in the UK suffer from heart disease. The general term for heart disease is cardiomyopathy, a condition in which the walls of the heart chambers have become stretched, thickened or stiff.

GETTY-STOCK

This affects the hearts ability to pump blood around the body. Some types of cardiomyopathy are inherited and it can affect children and younger people.

I couldnt walk up the stairs without having stabbing pains

Gordon Foster

In others, lifestyle factors such as smoking, an unhealthy diet or a sedentary lifestyle can be to blame. There is no cure and although it can be treated with drugs such as ACE inhibitors, they often have side effects and arent a permanent solution.

In Gordons case his condition was the result of a series of heart attacks, the first of which struck when he was 30.

I woke up one morning feeling horribly sick so I ran to the bathroom. I was banging my head on the floor to try to get rid of the pain in my chest, he recalls. Everybody thought I was a goner because it was such a massive heart attack.

Getty

1 of 11

10 Step plan to eliminate your risk of heart disease

Joanne and I got married two months later because she was worried I might not live until our wedding date.

However he did survive and he and Joanne went on to have two children, James, now 26, and Rebekah, 24. Then when James was just a year old Gordon had another heart attack and three years later, aged 37, he suffered a third.

He was diagnosed as suffering from heart failure which most commonly occurs following a heart attack when the heart muscle suffers irreparable damage.

Symptoms can include fatigue, shortness of breath and swelling. In severe cases people with heart failure are left unable to perform ordinary, day-to-day activities such as walking upstairs or are left breathless even when resting.

GETTY

By 2012 Gordons heart was functioning at just 17 per cent and he had been forced to retire on heart attack and three years later, aged 37, he suffered a third. from heart failure which most commonly occurs following a heart attack when the heart muscle suffers irreparable damage.

Symptoms can include fatigue, shortness of breath and swelling. failure are left unable to perform ordinary, day-to-day activities such as walking upstairs or are left breathless even when resting.

Functioning at just 17 per cent and he had been forced to retire on medical grounds from his job overseeing welding and fabricating sites.

For severely affected patients a heart transplant can be the only option but the chances of failure are high. Around 10 per cent of transplant patients die within a year of the operation and 25 per cent die within five years.

The need for treatment in this field has never been greater, says Professor Anthony Mathur, consultant cardiologist at St Bartholomews Hospital, London.

Now stem cell therapy is offering new hope to desperate patients and their families. The procedure involves extracting stem cells from bone marrow in the spine and injecting them into the heart.

Researchers hope that the stem cells, which are unique because they can grow into any type of body tissue, will grow into healthy heart cells and take over the work of the diseased or damaged ones.

GETTY-STOCK

The procedure takes about 20 minutes and patients can usually go home the following day. Gordon became the first man in the UK to be offered the operation under the Compassionate Treatment Programme funded by the Heart Cells Foundation charity at St Bartholomews Hospital after his doctor put him forward to take part in a trial.

The charity has so far raised more than 6.5million to fund the Stem Cell Research Programme and is campaigning to raise further cash to treat thousands more patients.

Stem cell therapy is still in the development and research stage and the Compassionate Treatment Programme is funded purely by the Heart Cells Foundation charity, says its chairman Jenifer Rosenberg.

To treat one person costs 10,000 so we need the continued support of our donors to save lives.

Getty Images

1 of 6

Queen Elizabeth II visits a ward during a tour of Great Ormond Street Hospital for sick children, 23rd July 1952

The treatment is currently in the second phase of clinical trials and phase three will start once funding is secured. If this is successful it is hoped that the treatment could eventually be offered on the NHS.

Gordon says he and his family will be forever thankful to the Heart Cells Foundation and his medical team at St Bartholemews for saving his life.

Without them, I believe I wouldnt be here today, he says. Im now able to lead a near-normal life and Im enjoying every moment I spend with my wife and children. I now live every day with hope.

Visit heartcellsfoundation.com

View original post here:
How a revolutionary stem cell treatment could save your heart - Express.co.uk

Posted in Cell Therapy | Comments Off on How a revolutionary stem cell treatment could save your heart – Express.co.uk

ViaCyte Raises $10M, Moves to Human Trial with New Diabetes Product – Xconomy

Posted: May 23, 2017 at 11:40 am

Xconomy San Diego

San Diego-based ViaCyte said it is ready to move into human testing with a new product intended for patients with Type 1 diabetes who are at high risk for acute, life-threatening complications from severe episodes of low blood sugar (hypoglycemia).

ViaCyte said Monday that healthcare regulators in both the United States and Canada have permitted the company to proceed with the early stage clinical trial, which calls for enrolling roughly 40 patients at medical centers that include UC San Diego and the University of Alberta in Edmonton, Canada. The goal of the trial is to assess the safety of the PEC-Direct product candidate and provide definitive evidence of efficacy.

According to ViaCyte, demonstrating efficacy with just 40 patients is a function of having a well-defined endpointdefined in this case as a clinically significant production of insulin in a patient population that has no ability to produce insulin when enrolled.

In a separate statement, ViaCyte said it has raised an additional $10 million to initiate the clinical trial and for other corporate purposes. Participants in the financing include the materials science company W.L. Gore & Associates, which is already working with ViaCyte, Asset Management Partners, and other undisclosed investors.

The non-profit research group JDRF also participated in the financing, according to the company.

Since 2004, when three companies merged to form what is now ViaCyte, the company has raised about $100 million from investors, and $75 million in project funding from JDRF and the California Institute for Regenerative Medicine (CIRM).

ViaCyte was founded to advance technology that encapsulates pancreatic progenitor cells (stem cells engineered to develop into fully differentiated pancreatic cells) within a semi-permeable membrane. This packet is implanted under the skin. Once the pancreatic cells develop fully, they secrete insulin and other hormones that pass through the membrane, similar to how tea seeps out of a tea bag. White blood cells are too big to penetrate the membrane, however, so the packet protects the implanted pancreatic cells from a patients own immune system.

In March, ViaCyte said it has been developing a new type of packet called PEC-Direct, for Type 1 diabetes patients who are prone to severe hypoglycemic episodes. The company has engineered this membrane so a patients blood vessels can grow through the membrane and connect directly with the stem cell-derived pancreatic cells. In this case, however, the membrane is not designed to protect against a patients immune system. So PEC-Direct patients would also get immune-suppressant drugs.

Insulin therapy has transformed Type 1 diabetes from a death sentence to a chronic illness, but it is far from a cure, said Paul Laikind, president and CEO of ViaCyte. Patients with Type 1 diabetes must still deal the daily impact of the disease and are at risk for long-term complications.

The company said PEC-Direct is targeting a subset of patients with Type 1 diabetes who are at high risk for life-threatening events because they are acutely vulnerable to severe hypoglycemic episodes, or they cant really tell when or if they are hypoglycemic.

ViaCyte estimates that about 140,000 people in the United States and Canada are at risk for severe hypoglycemic episodes.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788

View original post here:
ViaCyte Raises $10M, Moves to Human Trial with New Diabetes Product - Xconomy

Posted in Diabetes | Comments Off on ViaCyte Raises $10M, Moves to Human Trial with New Diabetes Product – Xconomy

Eric Paslay Treats Pediatric Diabetes Patients to a Private Concert and Compares Glucose Monitors! – PEOPLE.com

Posted: May 23, 2017 at 11:40 am

Its not always easy to be a kid with type 1 diabetes, and nobody knows that better thanEric Paslay.

But now that hes a successful country star, the She Dont Love You crooner, 34, wants to help young people who are living with the disease just like him. On Saturday, Paslay headed to Joslin Diabetes Center in Boston to chat with pediatric diabetes patients. In addition to giving a special private performance for the patients, Paslay engaged with the kids as they shared experiences about living with the autoimmune disease. He even compared glucose numbers with a few who had the same Dexcom monitor as him.

One patient asked him what it was like to live with diabetes on the road and Paslayemphasized the importance of always being aware and never being afraid to ask for help when it is needed. He also admitted he keeps a glass of orange juice nearby during all performances, including the one at Joslin, in case his blood sugar starts to dip.

Paslay, who has said hes definitely had scary moments on stage in the past, explained that his wifeNatalie and other members of his team can monitor his blood sugar level remotely while he is performing to watch out for trouble.

He really took the time to get to know our patients and bond with them about his own experiences living with type 1 diabetes, Dr. Peter Amenta, President and CEO of Joslin Diabetes Center, told PEOPLE. It was a very special day for all of us.

Paslay was in Boston to perform at the Massachusetts Fallen Heroes 2nd annual Patriot Fest concert, which he headlined with country singer Tyler Farr at the Lawn on D. While there, the two spent time with MA Gold Star family members and veterans at a private VIP meet and greet. Of course, he did manage to get in some down time: After the concert, he enjoyed clam chowder and crab cakes at Legal Sea Foods.

Follow this link:
Eric Paslay Treats Pediatric Diabetes Patients to a Private Concert and Compares Glucose Monitors! - PEOPLE.com

Posted in Diabetes | Comments Off on Eric Paslay Treats Pediatric Diabetes Patients to a Private Concert and Compares Glucose Monitors! – PEOPLE.com

Page 1,560«..1020..1,5591,5601,5611,562..1,5701,580..»